H

Hawaii Pacific Neuroscience | Clinical Research Center

Research site
(Unclaimed)
Location
2230 Liliha Street, Suite 104, Honolulu, Hawaii, United States of America

Site insights

Top conditions

Top treatments

XEN1101
LY573144
Pregabalin
Cenobamate
Buntanetap
Lasmiditan
Levodopa
LP352
TAK-994
BIIB076

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 39 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and toler...

Enrolling
Focal Onset Seizures
Drug: XEN1101
Drug: Placebo

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy...

Enrolling
Tremor
Parkinson Disease
Drug: Suvecaltamide
Drug: Placebo

This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatm...

Active, not recruiting
Essential Tremor
Drug: JZP385
Other: Placebo

In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study...

Enrolling
Parkinson Disease
Drug: BIIB122
Drug: BIIB122-Matching Placebo

This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety...

Enrolling
Upper Limb Spasticity
Biological: AboBoNT-A
Biological: OnaBoNT-A

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo
Locations recently updated

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Enrolling
Focal Epilepsy
Drug: BHV-7000
Drug: Placebo

The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and toler...

Active, not recruiting
Focal Epilepsy
Drug: XEN1101

In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or...

Enrolling
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease Dementia
Drug: BIIB080-matching placebo
Drug: BIIB080

The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment a...

Active, not recruiting
Alzheimer's Disease
Drug: Aducanumab
Drug: Placebo

This study will evaluate the long term safety, tolerability, PK, and efficacy of XEN1101 25 mg QD taken orally in subjects with Focal Onset Seizures...

Invitation-only
Tonic-Clonic Seizures
Focal Epilepsy
Drug: XEN1101

52 Week Open-Label Safety Study of Cenobamate for Subjects who Complete YKP3089C025 (core study)

Invitation-only
Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Drug: Cenobamate

This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects wil...

Active, not recruiting
Parkinson's Disease
Combination Product: ND0612 Solution for SC infusion
Drug: Placebo for Oral IR-LD/CD

The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with development...

Active, not recruiting
Developmental and Epileptic Encephalopathy
Lennox-Gastaut Syndrome
Drug: LP352, bexicaserin
Locations recently updated

This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and sy...

Enrolling
MSA - Multiple System Atrophy
Symptomatic Neurogenic Orthostatic Hypotension
Drug: Ampreloxetine
Drug: Placebo

This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures....

Enrolling
Primary Generalized Epilepsy
Drug: Placebo
Drug: Cenobamate

Trial sponsors

Biogen logo
A
SK Life Science logo
X
Jazz Pharmaceuticals logo
Lilly logo
L
Takeda logo
Viatris logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems